Castle Biosciences Financial Statements
NASDAQ: CSTLHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Castle Biosciences revenue and earnings
In fiscal 2025, Castle Biosciences generated $344.2 million in revenue, up 3.7% from fiscal 2024, its 7th consecutive year of revenue growth. Castle Biosciences reported a net loss of $24.2 million, compared with net income of $18.2 million a year earlier. Gross margin was 79.4% (down from 81.9%) and operating margin -12.4%.
Diluted earnings per share came in at -$0.83, down from $0.62. Over the last 5 fiscal years, CSTL's revenue has grown at a 40.6% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Castle Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 344.23M | 332.07M | 219.79M | 137.04M | 94.08M | 62.65M | 51.87M | 22.79M |
| Revenue growth (YoY) | +3.66% | +51.09% | +60.38% | +45.65% | +50.18% | +20.79% | +127.62% | — |
| Cost of Revenue | 71.03M | 60.20M | 44.98M | 32.01M | 15.82M | 9.69M | 7.31M | 5.30M |
| Gross Profit | 273.20M | 271.86M | 174.81M | 105.03M | 78.26M | 52.96M | 44.55M | 17.49M |
| Operating Expenses | 316.01M | 263.19M | 242.78M | 177.88M | 118.34M | 59.51M | 37.23M | 21.32M |
| Research & Development | 51.85M | 52.04M | 53.62M | 44.90M | 29.65M | 13.26M | 7.38M | 4.85M |
| Selling, General & Admin | 229.32M | 200.05M | 180.15M | 143.00M | 86.74M | 48.13M | 29.84M | 16.47M |
| Operating Income | -42.81M | 8.67M | -67.98M | -72.86M | -40.08M | -6.54M | 7.33M | -3.84M |
| Interest Expense | 86.00K | 577.00K | 11.00K | 17.00K | 1.00K | 2.63M | 4.57M | 2.27M |
| Other Income (Expense) | 144.00K | 0 | 0 | — | — | 0 | -2.93M | -272.00K |
| Income Tax | -5.36M | 3.32M | 101.00K | -1.77M | -8.72M | 84.00K | 72.00K | 9.00K |
| Net Income | -24.16M | 18.25M | -57.47M | -67.14M | -31.29M | -10.28M | 5.28M | -6.37M |
| Net Income growth (YoY) | -232.41% | — | — | — | — | -294.88% | — | — |
| EPS (Basic) | -0.83 | 0.66 | -2.14 | -2.58 | -1.24 | -0.54 | 0.35 | -5.33 |
| EPS (Diluted) | -0.83 | 0.62 | -2.14 | -2.58 | -1.24 | -0.54 | -0.21 | -5.33 |
| Shares Outstanding (Basic) | 28.99M | 27.78M | 26.80M | 26.05M | 25.14M | 18.93M | 8.58M | 1.91M |
| Shares Outstanding (Diluted) | 28.99M | 29.25M | 26.80M | 26.05M | 25.14M | 18.93M | 8.66M | 1.91M |
| EBITDA | -2.04M | 24.67M | -55.65M | -62.31M | -36.67M | -6.07M | 7.68M | -3.55M |
| Gross Margin | 79.37% | 81.87% | 79.53% | 76.64% | 83.18% | 84.54% | 85.91% | 76.75% |
| Operating Margin | -12.44% | 2.61% | -30.93% | -53.16% | -42.60% | -10.44% | 14.13% | -16.83% |
| Net Margin | -7.02% | 5.49% | -26.15% | -48.99% | -33.26% | -16.42% | 10.17% | -27.94% |
This table shows 8 annual periods of Castle Biosciences's income statement, from FY 2025 back to FY 2018, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CSTL's reporting calendar. What is a income statement?